Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
FP02 - Health Services Research/Health Economics
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Type: Posters (Featured)
- Track: Health Services Research/Health Economics
-
+
FP02.03 - Changing Survival and Treatment Patterns in Patients Aged 80 or Older with Stage IV Non-Small Cell Lung Cancer (NSCLC)
00:00 - 00:00 | Presenter: Matthew Anaka
- Abstract
Loading...
-
+
FP07 - Pathology
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Type: Posters (Featured)
- Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
-
+
FP07.07 - Value of the Lung Immune Prognostic Index (LIPI) As a Prognostic Tool for Real-World Patients Treated for Mutation-Positive Metastatic NSCLC
00:00 - 00:00 | Presenter: Amanda Jane Williams Gibson
- Abstract
Loading...
-
+
P09 - Health Services Research/Health Economics - Real World Outcomes
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Health Services Research/Health Economics
-
+
P09.04 - Changing Survival and Treatment Patterns in Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC) in Alberta, Canada
00:00 - 00:00 | Presenter: Matthew Anaka
- Abstract
Loading...
-
+
P16 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Novel Immunotherapeutics (Translational)
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
P16.02 - Impact of Number and Location of Metastatic Sites on Survival in Stage IV ICI-Treated NSCLC
00:00 - 00:00 | Presenter: Amanda Jane Williams Gibson
- Abstract
Loading... -
+
P16.03 - Early Mortality Associated Factors With Immune Checkpoint Inhibition in Real-World Canadian NSCLC Patients
00:00 - 00:00 | Presenter: Amanda Jane Williams Gibson
- Abstract
Loading...
-
+
P36 - Pathology - Prognosis
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
-
+
P36.05 - Metastatic NSCLC Outcomes With Guideline-Recommended Treatment By KRAS Subtype
00:00 - 00:00 | Presenter: Anifat Elegbede
- Abstract
Loading...
-
+
P50 - Small Cell Lung Cancer/NET - Real World Outcomes
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Small Cell Lung Cancer/NET
-
+
P50.01 - A Year Experience With Atezolizumab Plus Chemotherapy For Small Cell Lung Cancer In Alberta, Canada
00:00 - 00:00 | Presenter: Anifat Elegbede
- Abstract
Loading... -
+
P50.02 - Survival Outcome Comparison in Metastatic Small Cell Lung Cancer (SCLC) at Diagnosis Versus at Relapse
00:00 - 00:00 | Presenter: Anifat Elegbede
- Abstract
Loading... -
+
P50.10 - Intravenous (IV) versus IV/oral route of etoposide administration: impact on real-world SCLC survival outcomes
00:00 - 00:00 | Presenter: Anifat Elegbede
- Abstract
Loading...
-
+
P76 - Targeted Therapy - Clinically Focused - EGFR
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P76.17 - Prognostic Role of the Systemic Immune-Inflammatory Index (SII) in Driver-Mutation Positive NSCLC: Real-World EGFR-Mutant Disease
00:00 - 00:00 | Presenter: Amanda Jane Williams Gibson
- Abstract
Loading...
-
+
P89 - Targeted Therapy - Clinically Focused - Translational
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P89.12 - Real World Outcomes in EGFR-Mutant Relapsed and De Novo Stage IV Non-Small Cell Lung Cancer (NSCLC)
00:00 - 00:00 | Presenter: Amanda Jane Williams Gibson
- Abstract
Loading...
